Meridian Clinical Research
Welcome,         Profile    Billing    Logout  
 5 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Essink, Brandon
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT06374394: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Recruiting
3
850
Europe, US
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
12/24
05/25
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Active, not recruiting
1/2
1015
US
31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™
Vaxcyte, Inc.
Pneumococcal Vaccines
09/24
09/24
NCT05089630: A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Active, not recruiting
1/2
329
US
Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline)
GlaxoSmithKline
Cytomegalovirus Infections
06/29
06/29
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting
1c
63
US
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Meissa Vaccines, Inc.
Respiratory Syncytial Virus (RSV)
10/23
10/23
NCT05664334: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Completed
1
140
US
IVX-121, IVX-241, Placebo, MF59®
Icosavax, Inc.
Healthy
01/24
01/24
NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Completed
1
180
US, RoW
CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (75 μg), CV0501 (100 μg), CV0501 (150 μg), CV0501 (200 μg)
GlaxoSmithKline
COVID-19, SARS-CoV-2
08/23
08/23
NCT03569514: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Not yet recruiting
N/A
10
NA
AIGIV, ANTHRASIL®
Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services
Anthrax
07/26
07/26
NCT03569553: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Not yet recruiting
N/A
100
NA
AIGIV, ANTHRASIL®
Emergent BioSolutions, Centers for Disease Control and Prevention, Department of Health and Human Services
Inhalational Anthrax
07/26
07/26
Johnson, Megan
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Active, not recruiting
4
3000
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
06/24
12/24
FORWARD PAD, NCT05858905: IDE Study With the Shockwave Mini S IVL Catheter

Active, not recruiting
N/A
75
US
Intravascular Lithotripsy
Shockwave Medical, Inc.
Peripheral Arterial Disease
04/24
04/25
NCT04982757: Accelerated TMS for Depression and OCD

Recruiting
N/A
300
US
MagVenture MagPro System with Brainsight neuronavigation device
Weill Medical College of Cornell University, The New Venture Fund / Foundation for OCD Research, The Wellcome Leap Fund
Depression, OCD
05/26
08/26
Nichols, Amy
PATENT-E, NCT05561114: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

Recruiting
3
198
US
GIE Medical ProTractX3 TTS DCB, Control
GIE Medical
Esophageal Stricture
07/24
12/29
PATENT-B, NCT05561127: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

Recruiting
3
171
US
GIE Medical ProTractX3 TTS DCB, Control
GIE Medical
Bowel; Stricture
09/24
03/29
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Recruiting
2
75
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
03/25
08/25
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting
1c
63
US
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Meissa Vaccines, Inc.
Respiratory Syncytial Virus (RSV)
10/23
10/23
OAT-FEED, NCT05229432: Study of Gastric Motility in Eosinophilic Gastritis

Recruiting
N/A
30
US
Children's Hospital Medical Center, Cincinnati
Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder
05/25
06/25
Wilson, Christine
NCT06195007: Motivational Interviewing for Stroke

Recruiting
N/A
86
US
Motivational Interview
University of Florida, Accreditation Council for Graduate Medical Education
Acute Stroke, Transient Ischemic Attack
07/25
07/25
Raiser, Frederick
NCT04971109: Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day

Completed
3
467
US
TPOXX, tecovirimat, ST-246, TPOXX Placebo, Placebo
SIGA Technologies, United States Department of Defense
Smallpox
05/23
05/23
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Active, not recruiting
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
11/24
RGT001-075-203, NCT06277934: A Study of RGT001-075 in Adult Patients With Obesity

Active, not recruiting
2
73
US
RGT001-075, Active drug, Placebo, Placebo drug
Regor Pharmaceuticals Inc.
Obesity
06/24
07/24
NCT05736835: A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

Active, not recruiting
2
227
US
CVXGA, PIV5-SARS CoV-2
CyanVac LLC
COVID-19
04/24
10/24
VLA1601-102, NCT06334393: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Recruiting
1
150
US
VLA1601, CpG 1018®, 3M-052-AF
Valneva Austria GmbH
Zika, Zika Virus Infection
12/24
12/25
Buettner, Andy
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Active, not recruiting
1/2
1015
US
31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™
Vaxcyte, Inc.
Pneumococcal Vaccines
09/24
09/24
Nemecek, Tiffany
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23

Download Options